The Utility of CAR-Modified T Cells in Myeloid Malignancies

February 18, 2014
Renier J. Brentjens, MD, PhD

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the utility of CAR-modified T cells in myeloid malignancies.

Clinical Pearls

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the utility of CAR-modified T cells in myeloid malignancies.

  • Ideally, CAR-modified T cells should have utility in myeloid malignancies
  • Identifying a target for CAR-modified T cells to recognize remains a challenge
  • There is always the danger of targeting a protein expressed on normal tissues or stem cells